Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N8-GP in previously untreated pediatric patients with severe hemophilia A
NCT02137850Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2014
- Primary completion
- Jun 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 23
01
Overview
A Phase 3 trial of turoctocog alfa pegol in hemophilia A, sponsored by Novo Nordisk. Started Jun 2014; status: completed.
02
Drugs
turoctocog alfa pegol
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT02137850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02137850.